Quadruplets, Maintenance, and More: The Future of Therapy for Newly Diagnosed Multiple Myeloma
- 1 September 2021
- journal article
- abstracts
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 21, S159-S160
- https://doi.org/10.1016/s2152-2650(21)01248-9
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trialBlood, 2020
- Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trialThe Lancet, 2019
- Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myelomaBlood, 2019
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 studyThe Lancet, 2019
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated MyelomaThe New England Journal of Medicine, 2019
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for MyelomaThe New England Journal of Medicine, 2017
- Autologous Transplantation and Maintenance Therapy in Multiple MyelomaThe New England Journal of Medicine, 2014
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple MyelomaThe New England Journal of Medicine, 2012
- Lenalidomide after Stem-Cell Transplantation for Multiple MyelomaThe New England Journal of Medicine, 2012